For cell and gene therapy, a consistent supply of quality starting material is vital that is maintained throughout the ...

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...

Completed biopharma IPOs that raised more than $100 million saw a twofold increase during the year. Biopharmaceutical initial ...

Non-profit organisations provide an alternative to rescue stalled orphan drugs for biotechs struggling against a lethargic ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to oral therapy ...

The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new ...

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...

Download our guide to the digital therapeutics landscape, key providers, and market trends. Discover how digital health solutions can enhance pharmaceutical outcomes.

The Weill Cancer Hub East has been established to explore the “interplay” between nutrition and immunotherapy in cancer ...

Genmab has received approval from Japan's Ministry of Health, Labour and Welfare for its Tivdak to treat cervical cancer.